This question tests monitoring priorities when initiating ACE inhibitors in patients with risk factors for adverse effects. The patient has two significant risk factors for ACE inhibitor-induced hyperkalemia and acute kidney injury: concurrent NSAIDs (ibuprofen) and diuretic therapy (hydrochlorothiazide). The triple combination of ACE inhibitor + NSAID + diuretic significantly increases risk of renal dysfunction. Monitoring potassium and creatinine within 1-2 weeks is essential to detect these complications early. INR monitoring (choice B) is not relevant as lisinopril doesn't affect coagulation. Creatine kinase (choice C) monitors for statin myopathy, not ACE inhibitor effects. TSH monitoring (choice D) is not indicated for ACE inhibitors. When starting ACE inhibitors in patients taking NSAIDs or diuretics, check renal function and potassium within 1-2 weeks, and counsel patients to minimize NSAID use when possible.

This question tests recognition of the simvastatin-amlodipine drug interaction and appropriate management. Amlodipine is a moderate CYP3A4 inhibitor that increases simvastatin exposure, with FDA guidance limiting simvastatin to 20 mg daily when used with amlodipine due to increased myopathy risk. The patient's new muscle aches suggest possible statin myopathy from this interaction. Switching to atorvastatin 40 mg avoids the dose limitation while maintaining potent statin therapy for her coronary artery disease. Adding gemfibrozil (choice A) would dangerously increase myopathy risk. Increasing simvastatin to 80 mg (choice B) violates FDA recommendations and worsens toxicity risk. Reducing amlodipine (choice D) may compromise blood pressure control. When patients on amlodipine require statin doses above simvastatin 20 mg daily, switch to atorvastatin or rosuvastatin, which have no dose restrictions with amlodipine.

This question tests management of the warfarin-amiodarone drug interaction. Amiodarone is a potent CYP2C9 inhibitor that significantly increases warfarin levels, typically causing INR elevation within 1-2 weeks of initiation. The patient's INR of 4.6 (goal 2-3) after 10 days of amiodarone confirms this interaction. Holding one warfarin dose and reducing the weekly dose by 30-50% with close monitoring is the appropriate management strategy. Continuing without adjustment (choice A) ignores the documented interaction and elevated INR. The INR goal remains 2-3 for atrial fibrillation, not 3-4 (choice C). Discontinuing amiodarone (choice D) is inappropriate as it was likely started for rhythm control. When initiating amiodarone in patients on warfarin, empirically reduce warfarin dose by 30-50% and monitor INR closely, as the interaction can persist for weeks after amiodarone discontinuation due to its long half-life.

This question tests management of drug interactions affecting antiplatelet therapy efficacy. Omeprazole inhibits CYP2C19, the enzyme responsible for converting clopidogrel to its active metabolite, potentially reducing its antiplatelet effect and increasing cardiovascular risk. This is particularly concerning in a patient recently hospitalized for TIA who needs optimal secondary stroke prevention. Switching to pantoprazole, which has minimal CYP2C19 inhibition, maintains gastroprotection while preserving clopidogrel efficacy. Continuing the combination (choice A) ignores FDA warnings about this interaction. High-intensity statins are indicated, not contraindicated, after TIA (choice C). Adding warfarin (choice D) isn't appropriate for TIA and would increase bleeding risk with dual therapy. When patients require both clopidogrel and PPI therapy, use pantoprazole or lansoprazole instead of omeprazole or esomeprazole to avoid compromising antiplatelet efficacy.

This question tests recognition of symptomatic bradycardia caused by concurrent use of two negative chronotropic agents. The patient's heart rate of 44 bpm with hypotension and symptoms of dizziness/near-syncope indicates excessive AV nodal blockade from the combination of metoprolol (beta-blocker) and diltiazem (non-dihydropyridine calcium channel blocker). Discontinuing diltiazem and continuing metoprolol is the best choice because it eliminates the drug interaction while maintaining beta-blockade for the patient's stable angina. Continuing both agents with a diuretic (choice A) would worsen hypotension without addressing the bradycardia. Switching to carvedilol while continuing diltiazem (choice C) maintains the problematic combination. Reducing metoprolol while continuing diltiazem (choice D) may not adequately resolve the bradycardia. When patients develop symptomatic bradycardia from concurrent negative chronotropes, discontinue one agent rather than reducing doses of both.

This question tests recognition of metformin contraindications in chronic kidney disease. The patient's estimated creatinine clearance of 38 mL/min falls below the threshold for safe metformin use (eGFR <45 mL/min/1.73m²), requiring discontinuation to prevent lactic acidosis risk. With an A1c of 9.4% despite dual oral therapy, adding basal insulin is the most appropriate next step for this patient with reduced renal function. Adding pioglitazone (choice A) doesn't address the metformin contraindication. Simply reducing the metformin dose (choice B) is insufficient when eGFR is <45 mL/min/1.73m². Switching sulfonylureas (choice D) doesn't improve glycemic control or address the metformin issue. When patients with diabetes develop renal impairment with eGFR <45 mL/min/1.73m², metformin must be discontinued, and insulin therapy often becomes necessary for adequate glycemic control.

This question tests recognition and management of a severe hypersensitivity reaction to trimethoprim-sulfamethoxazole. The patient presents with diffuse hives and lip swelling (angioedema) within 2 days of starting the antibiotic, which is characteristic of a Type I hypersensitivity reaction. Immediate discontinuation and urgent referral is the best choice because angioedema can progress to life-threatening airway obstruction. Adding diphenhydramine while continuing the offending drug (choice B) is dangerous and inappropriate. Switching antibiotics without prescriber contact (choice C) exceeds pharmacist scope and doesn't address the acute reaction. The timing and presentation are inconsistent with ACE inhibitor cough (choice D), which is a dry cough without urticaria or angioedema. When patients develop angioedema or severe urticaria from any medication, immediate discontinuation and urgent medical evaluation are mandatory, with documentation of the allergy to prevent future exposure.

This question tests the recognition and management of hypoglycemia in type 2 diabetes patients on multiple antidiabetic agents. The key patient-specific factor is the recent glipizide dose increase leading to frequent hypoglycemia symptoms with an A1c of 6.4%, indicating overtreatment. Discontinuing glipizide while continuing insulin glargine and metformin is the best choice because sulfonylureas like glipizide carry a high risk of hypoglycemia, especially in older adults, and removal reduces this risk without compromising control given the low A1c. Decreasing insulin glargine while continuing glipizide is suboptimal as it does not address the primary culprit, and switching to glyburide worsens hypoglycemia risk due to its longer duration. Increasing metformin or continuing glipizide ignores the hypoglycemia and may not adequately mitigate risks. A key clinical pearl is to prioritize de-escalation of high-hypoglycemia-risk agents like sulfonylureas when A1c is below 7% in older patients. Use a framework of assessing A1c, hypoglycemia frequency, and agent risk profiles to guide deprescribing in diabetes management.

This question tests the management of probable penicillin allergy during antibiotic therapy. The key patient-specific factor is hives and itching after the second amoxicillin dose, suggesting an IgE-mediated reaction requiring avoidance. Stopping amoxicillin, contacting the prescriber for an alternative, and documenting the allergy is best to prevent escalation to anaphylaxis. Continuing with diphenhydramine, switching to ampicillin, or increasing dose risks severe reactions. A clinical pearl is that beta-lactam allergies should be clarified by reaction type, with immediate hypersensitivity warranting class avoidance. Use a framework of evaluating reaction timing and symptoms to guide discontinuation and allergy documentation for future prescribing.

This question tests the recognition of metformin contraindications in patients with impaired renal function. The key patient-specific factor is the eGFR of 26 mL/min/1.73 m², which is below the threshold for safe metformin use due to lactic acidosis risk. Discontinuing metformin and reassessing the glycemic regimen is the best choice as guidelines contraindicate metformin when eGFR is below 30 mL/min/1.73 m². Continuing or increasing metformin, adding glyburide, or switching to extended-release ignores the renal impairment and heightens adverse event risk. A clinical pearl is that metformin accumulation in CKD can lead to rare but serious lactic acidosis, necessitating prompt discontinuation. Apply a decision framework of routinely checking eGFR before and during metformin therapy, with discontinuation if below 30 mL/min/1.73 m² and alternative agents like SGLT2 inhibitors if appropriate.